What question did this study set out to answer?

Provide standardized laboratory procedures for the collection, preparation, instrument setup, and flow cytometric analysis of measurable residual disease (MRD) in pediatric B-acute lymphoblastic leukemia.

March 1, 2022Current Protocols

Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method

View Full Paper

Ask AI

Bookmark

Authors

MBMichael J. BorowitzJohns Hopkins University BWBrent L. WoodGoethe University Frankfurt MKMichael KeeneyLondon Health Sciences Centre

Discussion

Member takes

Implication

Laboratory protocol outlines standardized flow cytometry workflows for measurable residual disease detection in pediatric B-ALL, indicating reproducible methods to guide risk-directed therapy.

Key Points

Provide standardized laboratory procedures for the collection, preparation, instrument setup, and flow cytometric analysis of measurable residual disease (MRD) in pediatric B-acute lymphoblastic leukemia.
Protocols define procedures for specimen collection, shipping, storage, and multi-color antibody staining for flow cytometry.
Analysis workflows establish standardized gating parameters for identifying residual leukemic blasts following induction therapy, including alternative approaches for samples lacking CD19 expression.
Provides the validated standard operating procedure utilized by the Children's Oncology Group and multicenter trials supported by the Foundation for the National Institutes of Health.
Enables reproducible quantification of sub-microscopic residual leukemic clones to drive risk-stratified therapy adjustments across participating clinical centers.

Cite This Study

Borowitz et al. (2022) studied this question.

synapsesocial.com/papers/6a7413405e45dc7750a8cfcb https://doi.org/10.1002/cpz1.383

View Full Paper

Ask AI

Bookmark

Implication

Laboratory protocol outlines standardized flow cytometry workflows for measurable residual disease detection in pediatric B-ALL, indicating reproducible methods to guide risk-directed therapy.

Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method

Discussion

Member takes

Implication

Key Points

Cite This Study

Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider